Marksans Pharma enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


14,290	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
634	634	49.7	430	383
29.5	29.5	2.2	20.9	19.9
29.6	29.6	2.3	29.1	41.6
13,715	—	—	—	—
−605	−605	−47.3	−401	−341
₹302.66	—	—	—	—

3,082	3,082	251	2,115	1,807
1.0%	1.0%	0.9%	1.4%	2.3%
0.00×	—	—	—	—

4.32×	—	—	—	—
19.22×	—	—	—	—
22.36×	—	—	—	—
41.87×	—	—	—	—
3,172	2,951	262	2,177	1,852
714	601	52.9	459	339
613	502	44.5	384	287
—	458	20.7	230	237
328	328	3.4	21.6	184
—	327	2.7	20.2	182
—	131	17.3	209	53.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health

₹ CrorePeersGRANULES METROPOLIS PARKHOSPS JLHL HCG RUBICON SHILPAMED SPARCMcap ₹14,290 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	14,290.4
- Cash, Equiv & ST Investments	383.0	430.3	49.7	634.1	634.1
+ Minority Interest	19.9	20.9	2.2	29.5	29.5
+ Total Debt	41.6	29.1	2.3	29.6	29.6
Enterprise Value	—	—	—	—	13,715.4
Net Debt (memo)	-341.4	-401.2	-47.3	-604.5	-604.5
EV per Share	—	—	—	—	302.66

Total Capital	1,806.7	2,115.0	251.2	3,082.3	3,082.3
Total Debt/Total Capital	2.30	1.38	0.92	0.96	0.96
Total Debt/EV	—	—	—	—	0.00

EV/Sales	—	—	—	—	4.32
EV/EBITDA	—	—	—	—	19.22
EV/EBIT	—	—	—	—	22.36
EV/Free Cash Flow	—	—	—	—	41.87
Reference Items — Trailing FY Values
Sales	1,852.1	2,177.4	262.3	2,950.9	3,171.7
EBITDA	339.3	458.6	52.9	600.8	713.7
EBIT	287.5	384.3	44.5	502.1	613.3
Operating Cash Flow	237.4	230.4	20.7	458.1	—
Free Cash Flow	183.8	21.6	3.4	327.6	327.6
FCFF (free cash flow to the firm)	181.8	20.2	2.7	326.9	—
Capital Expenditure	53.6	208.8	17.3	130.5	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.